Scarica l'app Stockscreener
2.02
0.98%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - Insider Monkey
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace
AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks
AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com
AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus
AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus
AbCellera gains Health Canada nod for AD antibody trial - Investing.com
Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN
AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault
Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus
Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia
Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus
Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus
Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st
Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - Yahoo Finance
AbCellera to begin Phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment - marketscreener.com
AbCellera to begin Phase 1 trial for menopause treatment - Investing.com
AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Trea - GuruFocus
AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Treatment | ABCL Stock News - GuruFocus
AbCellera Receives Authorization From Health Canada To Initiate The Phase 1 Clinical Trial Of Abcl635 For Vasomotor Symptoms Due To Menopause - marketscreener.com
AbCellera patent upheld in Federal Circuit Court ruling By Investing.com - Investing.com Nigeria
AbCellera Wins Patent Appeal Against Bruker - TipRanks
AbCellera's Platforms - AbCellera
Making medicines together. We collaborate with partners to create differentiated antibody medicines. - AbCellera
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by t - GuruFocus
AbCellera (ABCL) Wins Patent Validation Case in Federal Circuit - GuruFocus
AbCellera patent upheld in Federal Circuit Court ruling - Investing.com Australia
Abcellera's Microfluidic Cell Culture Patent Affirmed Valid By U.S. Court Of Appeals For Federal Circuit - marketscreener.com
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - BioSpace
AbCellera plans to advance ABCL635 and ABCL575 into Phase 1 trials in Q3 2025 - MSN
AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Call Transcript - Insider Monkey
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2 - GuruFocus
Stifel Adjusts Price Target for AbCellera (ABCL), Maintains Buy Rating | ABCL Stock News - GuruFocus
AbCellera Biologics Navigates Progress and Challenges in Earnings Call - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - MSN
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting | ABCL Stock News - GuruFocus
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):